Neopterin in Acute Coronary Syndrome PatientsNCT05080387
Neopterin in Acute Coronary Syndrome Patients
An observational study of Neopterin in Acute Coronary Syndrome Patients, run by Assiut University at 1 site in Egypt.
Trial summary
Measurement of neopterin in ACS patients Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Neopterin in Acute Coronary Syndrome Patients
- What is being tested?
- Blood sample
- How many people
- 50 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Nov 2022to 1 Oct 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Adult, Older adult
Study population: All patients of sample size admitted to cardiology department with ACS.
Who may be able to join
- All patient of sample size admitted to cardiology departmentof Assiut university hospital with :
- Acute typical chest pain
- Positive cardiac enzymes
- ECG show recent ischemic changes
- ECHO show SWMA
Who cannot join
- Patients not fulfill inclusion criteria.
- Patients with other diseases which may cause increase of neopterin level as viral infections, intracellular bacteria or parasites infections, certain malignancies, allograft rejection
Trial locations and contacts
1 site in 1 country.
Yehia Taha keshik, Prof. Doctor contact
Egypt1 site, 1 recruiting
- Recruiting
Assiut university
Asyut, AssiutU
Yehia Taha keshik, Prof . Doctor, 01223971269
Magdy Ibrahim El desoky, Lecturer, 01279950400
About this study
Measurement of neopterin in ACS patients
Read the detailed description
- Detect level of neopterin in ACS patients to detect whether there is relation or not between ACS and neopterin
- Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS patients
- Detect relation between neopterin level and in hospital events
- Being tested
- Blood sample
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood sampleOther
Blood samples will obtained for measurement of neopterin level through ELIZA
What is being measured
The primary outcome is the main question the study is designed to answer.
To detect whether there is association between neopterin and ACS or not
To detect whether there is association between neopterin and ACS or not
Measured: 72 hours
Secondary outcomes (1)
Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS and detection of relation between neopterin level and in hospital events
Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS and detection of relation between neopterin level and in hospital events
Measured: 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2021
- Study start1 Nov 2022 (estimated)
- Primary completion1 Oct 2023 (estimated)
- Study completion1 Oct 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neopterin in Acute Coronary Syndrome PatientsStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mina Khairy Alyshaa Gorgy, Assiut University
- Investigators
- Magdy Ibrahim Aldesowky, Lecturer, Principal investigator, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05080387
- Sponsor's protocol ID
- Neopterin
- Status last verified
- Oct 2021
- First submitted
- 5 Oct 2021
- Last updated
- 15 Feb 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Share if participants agree
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neopterin in Acute Coronary Syndrome Patients
- ClinicalTrials.gov ID
- NCT05080387
- Acronym / sponsor ID
- Neopterin
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Nov 2022 (estimated)
- Primary completion
- 1 Oct 2023 (estimated)
- Study completion
- 1 Oct 2024 (estimated)
- First posted
- 15 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Measurement of neopterin in ACS patients
Detailed description
- Detect level of neopterin in ACS patients to detect whether there is relation or not between ACS and neopterin
- Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS patients
- Detect relation between neopterin level and in hospital events
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All patients of sample size admitted to cardiology department with ACS.
Key inclusion criteria (5 listed)
- All patient of sample size admitted to cardiology departmentof Assiut university hospital with :
Key exclusion criteria (2 listed)
- Patients not fulfill inclusion criteria.
- Patients with other diseases which may cause increase of neopterin level as viral infections, intracellular bacteria or parasites infections, certain malignancies, allograft rejection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood sampleBlood samples will obtained for measurement of neopterin level through ELIZA | Other | – |
Primary outcome
To detect whether there is association between neopterin and ACS or not
Time frame: 72 hours
To detect whether there is association between neopterin and ACS or not
1 secondary outcome
Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS and detection of relation between neopterin level and in hospital events
Time frame: 72 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2022.
- Individual participant dataSharing planned: Undecided. Share if participants agree
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yehia Taha keshik, Prof. Doctor contact
Magdy Ibrahim Aldesowky, Lecturer principal investigator
Assiut University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neopterin in Acute Coronary Syndrome Patients, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Mina Khairy Alyshaa Gorgy, Resident (01227386406, Minakhairy1995@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To detect whether there is association between neopterin and ACS or not (time frame: 72 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2022.